Our study implies that postoperatively administered RAI at a dose of 30 mCi (1.1GBq) for tumor ablation might not be adequate for preventing recurrence in patients with intermediate-risk PTC with cN1b. The gene discussed is NT5C1B; the disease is neoplasm.